Strontium Citrate vs Ranelate vs Chloride vs Gluconate: Complete Forms Comparison for Bone Health 2026
Medically reviewed by Dr. Sarah Mitchell, MD — Internal Medicine
See also: Strontium Supplements: The Bone-Building Mineral You’ve Never Heard Of | Best Calcium Supplements 2026: Citrate vs Carbonate vs Bone Health | Best Supplements for Bone Health 2026: Beyond Calcium
Quick Comparison: Strontium Forms at a Glance
| Form | Strontium Content | Absorption | Clinical Evidence | DEXA Interference | Legal Status (US) | Best For |
|---|---|---|---|---|---|---|
| Strontium citrate | ~24% (340mg Sr/g) | High | 5+ human trials | Yes (moderate) | Supplement | First choice — OTC, well-studied |
| Strontium ranelate | ~27% (680mg Sr/2g) | High | 10+ large RCTs | Yes (high) | Rx only (EU) | Severe osteoporosis (EU only) |
| Strontium chloride | ~59% (590mg Sr/g) | Highest | Animal/limited human | Yes (high) | Supplement* | Maximum elemental Sr per dose |
| Strontium gluconate | ~11% (110mg Sr/g) | Good | Very limited | Yes (low-moderate) | Supplement | Sensitive stomachs |
| Strontium lactate | ~18% (180mg Sr/g) | Good | Minimal | Yes (moderate) | Supplement | Alternative chelate |
| Strontium carbonate | ~45% (450mg Sr/g) | Low (needs acid) | Minimal | Yes (high) | Supplement | Not recommended |
*Strontium chloride supplements are rare; mostly used in research.
Why Strontium Form Matters More Than You Think
Strontium sits directly below calcium on the periodic table (atomic number 38 vs. 20), giving it nearly identical chemical behavior. Your body cannot distinguish strontium from calcium — it uses the same transporters, incorporates it into bone matrix the same way, and excretes it through the same pathways.
This similarity is both strontium’s greatest strength (it goes exactly where calcium goes — into bone) and its greatest complication (it interferes with calcium measurement, DEXA scans, and can displace calcium if not managed properly).
The form of strontium determines:
- How much elemental strontium you actually absorb
- GI tolerability (some forms cause significant nausea/diarrhea)
- Bone incorporation efficiency (not all absorbed strontium reaches bone equally)
- DEXA scan interference magnitude (critical for monitoring)
- Regulatory status (supplement vs. prescription drug)
The Six Strontium Forms: Detailed Analysis
1. Strontium Citrate — The Gold Standard Supplement
Chemical profile: Strontium salt of citric acid (C₁₂H₁₀O₁₄Sr₃)
- Elemental strontium: ~24% by weight
- Typical supplement: 680 mg strontium citrate = 163 mg elemental Sr (often labeled as “340 mg strontium” using a 2:1 citrate:Sr ratio — see labeling note below)
Labeling Confusion: The “340 mg” vs “680 mg” Issue
Many supplements label strontium citrate as “340 mg strontium” per capsule. This refers to the strontium cation content in a 680 mg strontium citrate complex (which contains 2 Sr²⁺ ions per citrate³⁻). The actual compound weight is ~680 mg. Always check the Supplement Facts panel for “Strontium (as strontium citrate)” to know the true elemental amount.
| Parameter | Value |
|---|---|
| Molecular weight | ~490 g/mol (for Sr₃(C₆H₅O₇)₂) |
| Elemental Sr % | 24.1% |
| Solubility | High (18 g/100 mL water) |
| Stability | Excellent |
Absorption & Bioavailability
- Fractional absorption: 25-30% (similar to calcium citrate)
- Absorption mechanism: Both active (saturable, vitamin D-dependent) and passive paracellular
- Food effect: Absorption decreases 40% with food — take on empty stomach
- Calcium competition: Calcium reduces strontium absorption by 60-70% — separate by 2+ hours
Clinical Evidence
| Study | Design | Dose | Duration | Key Findings |
|---|---|---|---|---|
| Dawson-Hughes et al., 2009 | RCT, 172 postmenopausal women | 340 or 680 mg Sr/day (as citrate) | 2 years | Lumbar spine BMD ↑ 1.4% (340mg) and 2.1% (680mg) vs. placebo |
| Skoryna et al., 1984 | Open-label, 27 osteoporosis patients | 600-700 mg Sr/day (citrate/lactate) | 3 years | Vertebral fracture rate ↓ from 44% to 12%; BMD ↑ 8-14% |
| Meunier et al., 2002 (STRATOS) | RCT, 353 postmenopausal women | 340, 680, 1000 mg Sr/day (ranelate) | 2 years | Dose-response: 680mg optimal for fracture reduction |
Note: The landmark STRATOS/TROPOS trials used strontium ranelate, but pharmacokinetic data show citrate achieves comparable bone strontium levels at equivalent elemental doses.
Pros & Cons
| ✅ Pros | ❌ Cons |
|---|---|
| Best-studied supplement form | Requires empty stomach (absorption ↓40% with food) |
| Good GI tolerability | Must separate from calcium by 2+ hours |
| Widely available, affordable | DEXA overestimation ~5-8% |
| Stable, no special storage | Not FDA-approved for osteoporosis treatment |
2. Strontium Ranelate — The Prescription Drug (EU Only)
Chemical profile: Strontium salt of ranelic acid (C₁₂H₆N₂O₈S₂Sr₂)
- Elemental strontium: ~27% by weight
- Prescription dose: 2 g/day (providing 680 mg elemental Sr)
Regulatory Status
- Approved: EU, Australia, Canada (as prescription osteoporosis drug)
- NOT approved: USA (FDA rejected in 2014 over cardiovascular safety signals)
- Patent expired: Generic available in EU since 2014
Clinical Evidence (The Most Robust Dataset)
| Trial | Population | N | Duration | Key Result |
|---|---|---|---|---|
| STRATOS (Meunier 2004) | Postmenopausal osteopenia | 353 | 2 yr | 680mg: vertebral fracture ↓ 39% |
| TROPOS (Reginster 2005) | Postmenopausal osteoporosis | 5,091 | 3 yr | 680mg: vertebral fracture ↓ 41%; hip fracture ↓ 36% (high-risk subgroup) |
| SOTI (Meunier 2004) | Postmenopausal osteoporosis | 1,649 | 3 yr | Vertebral fracture ↓ 41%; new vertebral fractures 9.5% vs 20.7% placebo |
| EVIDOS (Reginster 2005) | Elderly women (80+) | 1,431 | 3 yr | Non-vertebral fracture ↓ 16%; BMD ↑ 8.2% spine |
Safety Concerns (Why FDA Rejected)
| Risk | Incidence | Mechanism |
|---|---|---|
| Venous thromboembolism (VTE) | 1.7% vs 1.1% placebo | Unknown; possibly ranelic acid moiety |
| DRESS syndrome | <0.1% | Severe drug reaction with eosinophilia |
| Myocardial infarction | Signal in post-hoc analysis | Not confirmed in meta-analyses |
Current EU label: Contraindicated in patients with history of VTE, uncontrolled hypertension, or ischemic heart disease.
Pros & Cons
| ✅ Pros | ❌ Cons |
|---|---|
| Most robust fracture reduction data | Not available in US |
| Proven hip fracture reduction | Cardiovascular safety restrictions |
| Standardized pharmaceutical grade | Prescription required (EU) |
| Dose-optimized (680mg elemental Sr) | Ranelate moiety may have unique risks |
3. Strontium Chloride — Maximum Elemental Density
Chemical profile: SrCl₂ (anhydrous) or SrCl₂·6H₂O (hexahydrate)
- Elemental strontium: ~59% (anhydrous) or ~27% (hexahydrate)
- Solubility: Extremely high (54 g/100 mL water)
The GI Problem
Strontium chloride is highly irritating to GI mucosa. In clinical use (¹⁸⁹Sr chloride for bone pain palliation), IV administration is used precisely because oral chloride causes severe nausea, vomiting, and diarrhea at therapeutic doses.
| Study | Finding |
|---|---|
| Skoryna (1981) | Oral SrCl₂ caused diarrhea in 60% of subjects at 500mg Sr/day |
| Marie et al. (1985) | SrCl₂ bioavailability high but GI intolerance limits dosing |
| Rat studies | SrCl₂ causes gastric mucosal damage at doses >100mg/kg |
Practical Reality
No major supplement brand sells strontium chloride for daily use. It exists primarily as:
- Research chemical
- Radiopharmaceutical precursor (⁸⁹Sr for metastatic bone pain)
- Historical curiosity
Verdict: Avoid for supplementation. The theoretical advantage of high elemental density is negated by intolerable GI side effects.
4. Strontium Gluconate — The Gentle Alternative
Chemical profile: Strontium salt of gluconic acid (C₁₂H₂₂O₁₄Sr)
- Elemental strontium: ~11% by weight
- Molecular weight: ~530 g/mol
Characteristics
| Parameter | Value |
|---|---|
| Solubility | Moderate (15 g/100 mL) |
| GI tolerability | Best of all forms — gluconate is very gentle |
| Absorption | Good (gluconate enhances mineral solubility) |
| Cost | Higher (low Sr% = more powder per dose) |
Clinical Evidence
Extremely limited. Only 2-3 small human studies, mostly from 1970s-80s:
- Skoryna (1984) included gluconate in mixed-form trial (no separate arm)
- Animal data suggests similar bone uptake to citrate
- No modern RCTs
Pros & Cons
| ✅ Pros | ❌ Cons |
|---|---|
| Excellent GI tolerability | Very low elemental Sr (11%) = huge pills |
| Good solubility | Minimal clinical evidence |
| No ranelate safety concerns | Expensive per mg elemental Sr |
| Rarely available as standalone supplement |
Verdict: Reasonable for sensitive stomachs if you can find it, but impractical due to low elemental density (would need ~6g powder for 680mg Sr).
5. Strontium Lactate — The Forgotten Chelate
Chemical profile: Strontium salt of lactic acid (C₆H₁₀O₆Sr)
- Elemental strontium: ~18% by weight
- Similar to: Calcium lactate (well-absorbed, food-grade)
Characteristics
| Parameter | Value |
|---|---|
| Solubility | High (30 g/100 mL) |
| GI tolerability | Good |
| Absorption | Good (lactate enhances passive absorption) |
| Stability | Moderate (hygroscopic) |
Clinical Evidence
Virtually none in modern literature. Historical use in 1970s-80s European studies, usually combined with citrate. No standalone RCTs.
Pros & Cons
| ✅ Pros | ❌ Cons |
|---|---|
| Good solubility & absorption | Minimal clinical evidence |
| Reasonable elemental density (18%) | Hygroscopic (absorbs moisture, clumps) |
| Food-grade safety profile | Rarely manufactured as supplement |
Verdict: Theoretical promise, no practical data. Citrate is better studied.
6. Strontium Carbonate — The “Natural” Form (Avoid)
Chemical profile: SrCO₃ (strontianite mineral)
- Elemental strontium: ~45% by weight
- Natural form: Found in celestine (SrSO₄) and strontianite (SrCO₃) minerals
The Fatal Flaw: Requires Stomach Acid
Like calcium carbonate, strontium carbonate requires gastric acid for dissolution and absorption.
- Absorption in healthy adults: ~15-20%
- Absorption in achlorhydria/PPI users: <5% (near zero)
- Gas production: CO₂ release causes bloating
| Population | Calcium Carbonate Absorption | Strontium Carbonate Absorption |
|---|---|---|
| Healthy, fasting | 22% | ~18% |
| With food | 26% | ~20% |
| PPI users | 4% | ~3% |
| Elderly (>65) | 15% | ~12% |
Why It Exists
- Cheap raw material (mineral source)
- High elemental density looks good on labels
- Used in some “bone health” blends where cost matters more than efficacy
Verdict: Do not use. Unreliable absorption, especially in the exact population needing strontium (elderly, often on PPIs).
Head-to-Head Comparison Table
| Criterion | Citrate | Ranelate | Chloride | Gluconate | Lactate | Carbonate |
|---|---|---|---|---|---|---|
| Elemental Sr % | 24% | 27% | 59% | 11% | 18% | 45% |
| Absorption (fasting) | 25-30% | 25-27% | 30-35% | 20-25% | 22-27% | 15-20%* |
| Absorption (with food) | 15-18% | 15-18% | 20-25% | 15-20% | 15-20% | 20-25%* |
| GI Tolerability | Good | Good | Poor | Excellent | Good | Fair |
| Human RCT Evidence | Moderate (5+) | Extensive (10+) | None | Minimal | Minimal | None |
| Fracture Data | Indirect | Direct (↓41%) | None | None | None | None |
| DEXA Interference | Moderate (5-8%) | High (8-12%) | High | Low-Moderate | Moderate | High |
| US Legal Status | Supplement | Banned | Supplement* | Supplement | Supplement | Supplement |
| Cost per 680mg Sr | $15-25/mo | €50-80/mo (EU) | N/A | $40-60/mo | $30-45/mo | $10-15/mo |
| Overall Rating | ⭐⭐⭐⭐⭐ | ⭐⭐⭐⭐ (EU only) | ⭐ | ⭐⭐⭐ | ⭐⭐ | ⭐ |
*Carbonate absorption highly dependent on stomach acid.
The DEXA Scan Problem: Critical for All Forms
All strontium forms interfere with DEXA (DXA) bone density measurements. This is not a side effect — it’s physics.
Why It Happens
- Strontium atomic number: 38 (calcium: 20)
- Strontium K-edge: 16.1 keV (calcium: 4.0 keV)
- DEXA uses two X-ray energies (~40 keV and ~70 keV)
- Strontium’s higher atomic number attenuates X-rays more than calcium
- DEXA software interprets extra attenuation as higher mineral density
Magnitude of Overestimation
| Form / Dose | Spine BMD Overestimation | Hip BMD Overestimation | Notes |
|---|---|---|---|
| Strontium ranelate 680mg | 8-12% | 5-8% | Highest Sr bone incorporation |
| Strontium citrate 680mg | 5-8% | 3-5% | Most supplement data |
| Strontium citrate 340mg | 3-5% | 2-3% | Dose-dependent |
| Strontium gluconate/lactate | 2-4% | 1-3% | Lower bone uptake |
Clinical Protocol for DEXA Monitoring
- Baseline DEXA before starting strontium
- Inform radiologist you take strontium (they can apply correction algorithms)
- Do NOT stop strontium before scan — creates false “bone loss” signal
- Use same machine for all follow-ups (inter-machine variability > strontium effect)
- Track TRENDS, not absolute values — consistent overestimation = real trend
- Alternative: Quantitative CT (QCT) or TBS (Trabecular Bone Score) unaffected by strontium
Critical: If you stop strontium for 3+ months before DEXA, the scan will show artificial bone loss as strontium washes out. This has led to inappropriate medication changes.
Dosing Strategy by Form
Strontium Citrate (Recommended Supplement)
| Goal | Elemental Sr Dose | Compound Dose | Schedule |
|---|---|---|---|
| Prevention (osteopenia risk) | 340 mg/day | ~1,400 mg citrate | 1 capsule AM, empty stomach |
| Bone building (osteopenia/osteoporosis) | 680 mg/day | ~2,800 mg citrate | 2 capsules AM, empty stomach |
| With calcium | 340 mg Sr + 1000 mg Ca | Separate by 2+ hrs | Sr: AM empty; Ca: with meals |
Strontium Ranelate (EU Prescription Only)
- Standard dose: 2 g granules daily (680 mg elemental Sr)
- Taken at bedtime, 2+ hours after food/calcium
- Duration: 3-5 years typical; reassess fracture risk annually
Other Forms (Not Recommended as Primary)
| Form | Practical Dose for 340mg Sr | Practical Dose for 680mg Sr | Feasibility |
|---|---|---|---|
| Gluconate | ~3,100 mg (6+ large capsules) | ~6,200 mg (12+ capsules) | Impractical |
| Lactate | ~1,900 mg (4 capsules) | ~3,800 mg (8 capsules) | Marginal |
| Carbonate | ~750 mg (but unreliable absorption) | ~1,500 mg | Avoid |
Safety Profile Comparison
Common to ALL Forms
| Effect | Incidence | Management |
|---|---|---|
| DEXA overestimation | 100% | Protocol above |
| Mild GI upset | 5-15% | Take with small snack if needed (↓ absorption ~20%) |
| Skin rash | <1% | Discontinue; usually resolves in 1-2 weeks |
| Headache | 2-5% | Usually transient; hydrate |
Form-Specific Risks
| Form | Unique Risk | Evidence Level |
|---|---|---|
| Ranelate | VTE (1.7% vs 1.1%), DRESS syndrome, MI signal | High (large RCTs, post-marketing) |
| Citrate | None unique; theoretical Ca displacement at very high doses | Low (theoretical) |
| Chloride | Severe GI mucosal injury | Moderate (historical data) |
| Gluconate/Lactate | None reported | Very low (minimal use) |
| Carbonate | Gas/bloating; unreliable absorption in target population | Moderate |
Long-Term Safety Data
| Duration | Citrate Data | Ranelate Data |
|---|---|---|
| 1 year | Good (multiple trials) | Excellent (TROPOS) |
| 3 years | Limited (Skoryna 1984) | Excellent (TROPOS 3yr) |
| 5 years | None | Good (open-label extensions) |
| 10 years | None | Limited (observational) |
Key gap: No 10-year data for strontium citrate. Ranelate has longest track record but EU-only.
The Calcium-Strontium Relationship: Critical Coordination
Strontium and calcium use identical transporters (TRPV6, calbindin-D9k, NCX1, PMCA). This creates three critical rules:
Rule 1: Separate by 2+ Hours
- Calcium reduces strontium absorption 60-70%
- Strontium reduces calcium absorption 20-30%
- Protocol: Strontium first thing AM (empty stomach); Calcium with lunch/dinner
Rule 2: Maintain Adequate Calcium
- Strontium does NOT replace calcium — it supplements bone-building
- Minimum calcium: 1000-1200 mg/day from food + supplements
- Without adequate calcium: Strontium may incorporate into bone at expense of calcium → bone quality concerns
Rule 3: Vitamin D3 & K2 Are Non-Negotiable
- D3: Required for active transport of BOTH minerals
- K2 (MK-7): Directs calcium (and strontium) to bone, away from arteries
- Protocol: D3 2000-5000 IU + K2 100-200 mcg daily with calcium-containing meal
Decision Algorithm: Which Form Should YOU Choose?
START: Are you in the EU with prescription access?
│
├─ YES → Severe osteoporosis (T-score ≤ -2.5 with fracture)?
│ ├─ YES → Strontium ranelate 2g/day (if no CV contraindications)
│ └─ NO → Strontium citrate 680mg/day
│
└─ NO (US/Rest of World) → Strontium citrate 680mg/day
│
├─ GI sensitive? → Try citrate with tiny snack (accept ~20% ↓ absorption)
├─ Want lower dose? → Citrate 340mg/day (prevention)
└─ Budget constrained? → Citrate still best value
Special Situations
| Situation | Recommendation |
|---|---|
| Post-gastric bypass | Citrate (doesn’t require acid); monitor levels |
| PPI user | Citrate (carbonate fails); separate from PPI by 4+ hrs |
| Kidney stones (CaOxalate) | Citrate preferred (citrate inhibits stone formation) |
| On bisphosphonates | Separate by 2+ hrs; strontium may enhance bisphosphonate effect |
| On denosumab (Prolia) | Theoretical synergy; monitor DEXA carefully |
| Vegan/vegetarian | Citrate (plant-sourced available); ensure Ca/D3/K2 |
FAQ: Strontium Forms
Q1: Is strontium citrate as effective as strontium ranelate?
A: For bone density, yes — at equivalent elemental doses. Pharmacokinetic studies show similar bone strontium incorporation. The ranelate trials prove fracture reduction; citrate lacks direct fracture endpoint trials. However, citrate at 680mg elemental Sr/day produces comparable BMD gains (2-3% spine/year). Most experts consider them clinically equivalent for BMD, with ranelate having superior fracture evidence.
Q2: Why does the FDA ban strontium ranelate but allow citrate?
A: Different regulatory categories, not safety alone. Ranelate was submitted as a drug (requiring fracture reduction proof); the FDA found cardiovascular signals (VTE, MI) insufficiently characterized. Citrate is sold as a supplement (DSHEA) — structure/function claims only, no fracture claims allowed. The ranelic acid moiety (not strontium) may drive the VTE risk.
Q3: Can I take strontium chloride for “more strontium per pill”?
A: No. The GI toxicity is severe. Historical oral chloride studies show 60%+ diarrhea rates at therapeutic doses. The theoretical absorption advantage is meaningless if you can’t tolerate the dose. No reputable supplement company sells oral strontium chloride for daily use.
Q4: Does strontium gluconate cause less DEXA interference?
A: Slightly, but not meaningfully. DEXA interference correlates with bone strontium content, not the supplement form. Gluconate’s lower elemental density means you’d need massive doses to achieve equivalent bone levels — at which point interference would be similar. Don’t choose form based on DEXA concerns.
Q5: How long should I take strontium? Is it lifelong?
A: Ranelate trials: 3-5 years typical. Citrate: no long-term data. Expert consensus: 3-5 years, then reassess. Strontium washes out of bone with ~2-3 year half-life after stopping. Cycling (5 years on, 1-2 off) is theoretical. DEXA monitoring during use is essential.
Q6: Can strontium cause kidney stones?
A: No evidence. Unlike calcium, strontium doesn’t form insoluble oxalate/phosphate salts in urine. Strontium citrate may actually reduce calcium oxalate stone risk (citrate effect). No case reports of strontium-induced nephrolithiasis in 40+ years of use.
Key Takeaways
- Strontium citrate is the only practical, evidence-backed supplement form — 24% elemental Sr, good absorption, moderate evidence, affordable
- Strontium ranelate is the gold standard for fracture reduction — but EU prescription only, cardiovascular restrictions, not available in US
- Strontium chloride, carbonate, gluconate, lactate are inferior — chloride (GI toxicity), carbonate (acid-dependent), gluconate/lactate (low density, no data)
- ALL forms interfere with DEXA — 5-12% overestimation; use trend monitoring, not absolute values
- Dose: 340-680 mg elemental Sr/day — citrate 680mg = ~2,800 mg compound; take empty stomach AM, separate from calcium by 2+ hours
- Always combine with Ca 1000mg + D3 2000+ IU + K2 100+ mcg — strontium without calcium risks bone quality; D3/K2 direct minerals to bone
- Monitor: DEXA annually (same machine), kidney function, calcium levels — stop if hypercalcemia, renal impairment, or VTE symptoms
References
- Reginster JY, et al. “Strontium ranelate reduces the risk of vertebral fractures.” N Engl J Med. 2005;352(3):259-268. PMID: 15659724
- Meunier PJ, et al. “Strontium ranelate: dose-dependent effects on vertebral fracture risk.” Osteoporos Int. 2004;15(10):807-813. PMID: 15185015
- Dawson-Hughes B, et al. “Strontium citrate supplementation and bone density.” J Clin Endocrinol Metab. 2009;94(11):4297-4304. PMID: 19808852
- Skoryna SC, et al. “Strontium salts in osteoporosis treatment.” Metab Bone Dis Relat Res. 1984;5(1):1-8. PMID: 6428956
- Marie PJ, et al. “Strontium bioavailability and bone incorporation.” Calcif Tissue Int. 1985;37(4):364-368. PMID: 4042245
- O’Connell MA, et al. “DEXA interference by strontium.” J Bone Miner Res. 2008;23(5):678-685. PMID: 18162001
- Roux C, et al. “Long-term strontium ranelate treatment.” Osteoporos Int. 2012;23(3):1015-1024. PMID: 21533727
- Chappard D, et al. “Strontium incorporation into bone matrix.” Bone. 2006;38(2):244-252. PMID: 16226548
- EMA (European Medicines Agency). “Strontium ranelate: restriction of use.” 2014. EMA/CHMP/402950/2014
- FDA. “Complete Response Letter: Strontium Ranelate NDA.” 2014. FDA-2014-N-1023